000893828 001__ 893828
000893828 005__ 20210810182032.0
000893828 0247_ $$2doi$$a10.3390/pharmaceutics13020295
000893828 0247_ $$2Handle$$a2128/28035
000893828 0247_ $$2altmetric$$aaltmetric:106337727
000893828 0247_ $$2pmid$$a33672398
000893828 0247_ $$2WOS$$aWOS:000622975900001
000893828 037__ $$aFZJ-2021-02867
000893828 082__ $$a610
000893828 1001_ $$00000-0002-3858-6460$$aGiesen, Beatriz$$b0
000893828 245__ $$aAugmented Therapeutic Potential of Glutaminase Inhibitor CB839 in Glioblastoma Stem Cells Using Gold Nanoparticle Delivery
000893828 260__ $$aBasel$$bMDPI$$c2021
000893828 3367_ $$2DRIVER$$aarticle
000893828 3367_ $$2DataCite$$aOutput Types/Journal article
000893828 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1625664812_20460
000893828 3367_ $$2BibTeX$$aARTICLE
000893828 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000893828 3367_ $$00$$2EndNote$$aJournal Article
000893828 520__ $$aGold nanoparticles (Au NPs) are studied as delivery systems to enhance the effect of the glutaminase1 inhibitor CB839, a promising drug candidate already in clinical trials for tumor treatments. Au NPs were synthesized using a bottom-up approach and covered with polymers able to bind CB839 as a Au-polymer-CB839 conjugate. The drug loading efficiency (DLE) was determined using high-performance liquid chromatography and characterization of the CB839-loaded NPs was done with various microscopic and spectroscopic methods. Despite the chemical inertness of CB839, Au NPs were efficient carriers with a DLE of up to 12%, depending on the polymer used. The therapeutic effect of CB839 with and without Au was assessed in vitro in 2D and 3D glioblastoma (GBM) cell models using different assays based on the colony formation ability of GBM stem cells (GSCs). To avoid readout disturbances from the Au metal, viability methods which do not require optical detection were hereby optimized. These showed that Au NP delivery increased the efficacy of CB839 in GSCs, compared to CB839 alone. Fluorescent microscopy proved successful NP penetration into the GSCs. With this first attempt to combine CB839 with Au nanotechnology, we hope to overcome delivery hurdles of this pharmacotherapy and increase bioavailability in target sites.
000893828 536__ $$0G:(DE-HGF)POF4-5351$$a5351 - Platform for Correlative, In Situ and Operando Characterization (POF4-535)$$cPOF4-535$$fPOF IV$$x0
000893828 536__ $$0G:(DE-HGF)POF4-5353$$a5353 - Understanding the Structural and Functional Behavior of Solid State Systems (POF4-535)$$cPOF4-535$$fPOF IV$$x1
000893828 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000893828 7001_ $$0P:(DE-HGF)0$$aNickel, Ann-Christin$$b1
000893828 7001_ $$0P:(DE-Juel1)130525$$aBarthel, Juri$$b2
000893828 7001_ $$00000-0002-6288-9605$$aKahlert, Ulf Dietrich$$b3$$eCorresponding author
000893828 7001_ $$00000-0002-6021-1841$$aJaniak, Christoph$$b4$$eCorresponding author
000893828 773__ $$0PERI:(DE-600)2527217-2$$a10.3390/pharmaceutics13020295$$gVol. 13, no. 2, p. 295 -$$n2$$p295 -$$tPharmaceutics$$v13$$x1999-4923$$y2021
000893828 8564_ $$uhttps://juser.fz-juelich.de/record/893828/files/pharmaceutics-13-00295-v3.pdf$$yOpenAccess
000893828 909CO $$ooai:juser.fz-juelich.de:893828$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000893828 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)130525$$aForschungszentrum Jülich$$b2$$kFZJ
000893828 9131_ $$0G:(DE-HGF)POF4-535$$1G:(DE-HGF)POF4-530$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5351$$aDE-HGF$$bKey Technologies$$lMaterials Systems Engineering$$vMaterials Information Discovery$$x0
000893828 9131_ $$0G:(DE-HGF)POF4-535$$1G:(DE-HGF)POF4-530$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5353$$aDE-HGF$$bKey Technologies$$lMaterials Systems Engineering$$vMaterials Information Discovery$$x1
000893828 9141_ $$y2021
000893828 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000893828 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-05-04
000893828 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000893828 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-05-04
000893828 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-05-04
000893828 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-05-04
000893828 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPHARMACEUTICS : 2019$$d2021-05-04
000893828 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-04
000893828 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-04
000893828 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000893828 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000893828 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-05-04
000893828 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-05-04
000893828 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000893828 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-05-04
000893828 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000893828 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-05-04
000893828 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-05-04
000893828 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-05-04
000893828 920__ $$lyes
000893828 9201_ $$0I:(DE-Juel1)ER-C-2-20170209$$kER-C-2$$lMaterialwissenschaft u. Werkstofftechnik$$x0
000893828 980__ $$ajournal
000893828 980__ $$aVDB
000893828 980__ $$aUNRESTRICTED
000893828 980__ $$aI:(DE-Juel1)ER-C-2-20170209
000893828 9801_ $$aFullTexts